文献速递骨质疏松与代谢性骨病

地舒单抗诱导低钙血症的患病率:一项对注射后常规监测离子钙患者的回顾性观察研究

Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection.
PubMed 文献 · Osteoporos Int · 2023-09-26

该回顾性观察研究分析了2011至2020年间242例患者共1096次地舒单抗注射,每次注射后31天内常规监测离子钙。6.3%的注射后出现低钙血症(轻度4.6%、中度0.6%、重度1.1%),且与注射次数无关;重度低钙血症罕见(1%)。男性、严重肾衰竭、注射前低钙血症、低镁血症、低磷血症和维生素D不足是低钙血症的危险因素。

要点

  • 地舒单抗注射后低钙血症发生率为6.3%,重度低钙血症罕见(1.1%)。
  • 低钙血症发生率与注射次数无关(各次注射间波动于3-8%)。
  • 男性、严重肾衰竭、注射前低钙血症、低镁血症、低磷血症和维生素D不足是危险因素。

核心结论

  • 地舒单抗诱导的低钙血症是常见不良事件,其发生与注射次数无关。
  • 重度低钙血症罕见,严重肾衰竭和营养状态似乎是重要的预测因素。
  • 镁和磷可能为注射前风险评估增加价值,但这一观察需在更大队列中确认。

研究设计与样本

  • 回顾性观察研究,纳入2011至2020年间242例患者共1096次地舒单抗注射,每次注射后31天内常规监测离子钙。
  • 患者每人接受1-15次注射,首次注射平均年龄74±10岁,女性占88%。

主要发现

  • 全部注射中6.3%发生注射后低钙血症(轻度4.6%、中度0.6%、重度1.1%)。
  • 低钙血症发生率与注射次数无关(各次注射间波动于3-8%)。
  • 低钙血症的危险因素包括男性、严重肾衰竭、注射前低钙血症、低镁血症、低磷血症和维生素D不足。
  • 年龄较大与低钙血症风险增加无关。

临床怎么用

  • 作者认为,镁和磷可能为注射前风险评估增加价值,但这一观察需在更大队列中确认。

局限性

  • 镁和磷可能为注射前风险评估增加价值这一观察需在更大队列中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We assessed the prevalence of hypocalcemia after denosumab injections in a real-world cohort routinely monitored for calcium during up to 7.5 years of treatment. Among 1096 injections in 242 patients, 6.3% resulted in hypocalcemia, and was independent of the injection number. Severe hypocalcemia was rare (1%). PURPOSE: To assess the prevalence of and risk factors for hypocalcemia after administration of denosumab in a patient cohort routinely monitored for ionized calcium after each dose. METHODS: In this retrospective observational study, we analyzed denosumab-induced hypocalcemia in a real-world cohort who were routinely followed up with ionized calcium pre- and post-injection (within 31 days after injection) during the period 2011 to 2020. RESULTS: In total, we included data from 1096 denosumab injections in 242 individuals (1-15 injections per patient). The mean age for the first injection was 74 ± 10 years, and 88% were female. Post-injection hypocalcemia occurred after 6.3% of all injections (4.6% mild, 0.6% moderate, and 1.1% severe) and was independent of the number of injections (rate of hypocalcemia varied from 3-8%). Risk factors for hypocalcemia were male sex, severe renal failure, pre-injection hypocalcemia, hypomagnesemia, hypophosphatemia, and vitamin D insufficiency. Furthermore, older age was not associated with an increased hypocalcemia risk. CONCLUSIONS: Denosumab-induced hypocalcemia is a prevalent adverse event, which occurs independently of the number of injections. However, severe hypocalcemia is a rare occurrence, and severe renal failure and nutritional status appear to be important predictive factors. Magnesium and phosphate might add value in the pre-injection risk assessment; however, this observation needs to be confirmed in larger cohorts.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Spångeus A, Rydetun J, Woisetschläger M, et al. Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection. Osteoporos Int. 2023. PMID: 37750930. doi:10.1007/s00198-023-06926-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。